Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Performance of Unobserved Self-collected Nasal Swabs for Detection of SARS-CoV-2 by RT-PCR Utilizing a Remote Specimen Collection Strategy

Performance of Unobserved Self-Collected Nasal Swabs for Detection of SARS-CoV-2 by RT-PCR Utilizing a Remote Specimen Collection Strategy.

Authors: Kagan RM, Rogers AA, Borillo GA, Clarke NJ, Marlowe EM

Citation: Open Forum Infect Dis. 2021 Jan 28. doi: org/10.1093/ofid/ofab039 Online ahead of print.

Specialties: Infectious Disease, COVID-19

Download key summary

Related content

Audio Podcast
Alternative Specimen Collection Options
Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
Detection of SARS CoV 2 IgG Targeting Nucleocapsid or Spike Protein by Four High Throughput Immunoassays Authorized for Emergency Use

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.